Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

SHELTER PHARMA LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹41.66
at close · 27 Oct 2026
▼ 1.34 (-3.12%)

Latest filings

  1. Promoter Converts 4.65 Lakh Warrants Into Equity Shares · Fund Raising
  2. Board approves conversion of 465000 warrants into equity shares · Fund Raising
  3. Compliance certificate for share demat filed for quarter ended Sep 2026 · Compliance
All filings ↓
Ask Nexa about SHELTER PHARMA LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Makes and sells Ayurvedic and herbal healthcare products in two streams — human healthcare (45% of revenue) and veterinary/animal healthcare (55%) — across a portfolio of roughly 300 formulations from a manufacturing facility in Himatnagar, Gujarat. Revenue of ₹73.13 Cr in FY26 came from distribution across more than 15 Indian states and from exports to 8 countries including UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen and Sudan, with export revenue at ₹6 Cr (up 164% YoY). Distribution is being expanded through government procurement channels (state schemes, CSD, CGHS, KPKB) and a sales team that the company targets to double from about 80 people in the next two years. Materials (raw herbs, packaging and formulations inputs) are the dominant cost, eating 76% of revenue, with employee cost at 2.5% and other operating expenses at 4.1%. A second manufacturing facility near Ahmedabad (capex of ₹12-15 Cr, land already acquired for ₹2.5 Cr) is set to start installations from CY2027, and management has guided to an FY30 revenue target of ₹200 Cr.

Revenue mix · reported segments
Veterinary / animal healthcare products55.0%
Human healthcare products45.0%
Operating scale
Product portfolio
300 formulations (200 human + 100 veterinary)FY26
Geographic reach (India)
15+ states from Gujarat baseFY26
Export markets
8 countries (UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen, Sudan)FY26
Export revenue
₹6 Cr (up 164% YoY)FY26
Manufacturing facility
Himatnagar, Gujarat (can scale to ₹100 Cr revenue vs current ₹75 Cr)FY26
New manufacturing facility
Near Ahmedabad, ₹12-15 Cr capex, installations from CY2027FY26
Who pays it
Wholesalers, distributors and retailers across Indian states; government procurement (state schemes, CSD, CGHS, KPKB); export buyers such as Verka Dairies (Punjab), Genet International, Al-Saqr Agro and Taha Drugs & Chemicals (Sudan).
Biggest cost
Materials (herbs, packaging, formulation inputs) at 76% of revenue
Kind of business
Asset-light Ayurvedic formulations maker, zero-debt, expanding capacity and distribution
Where it sits
Small-cap (FY26 revenue ₹73.13 Cr) Ayurvedic/herbal healthcare company selling 300 formulations domestically and to 8 export markets, within an India Ayurvedic products market management sizes at ₹1,070 Bn in 2025.
Market Cap
₹69 Cr
P / E (TTM)
3.2×
EV / EBITDA
—
Div Yield
0.55%
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
16.0%▲
ROCE (FY26)
ROE — · margin —
Leverage
—·
Debt / Equity · borrowings not filed
Revenue FY24→FY26
1.8×▲
Revenue change
₹40 Cr → ₹73 Cr
Moves on a normal day
2.21%·
Median daily move
Last 248 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#2/158
ROCE#56/183
Revenue growth#10/161

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Returns on capital 16.0%
#56 of 183 in Pharmaceuticals on the latest reported figures
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SHELTER PHARMA LIMITED's filed financials and exchange disclosures

What does SHELTER PHARMA LIMITED do?

SHELTER PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

Does SHELTER PHARMA LIMITED pay a dividend?

Yes. The dividend yield is 0.55% at the current price.

Is SHELTER PHARMA LIMITED expensive compared with its peers?

On trailing P/E, SHELTER PHARMA LIMITED ranks 2 of 158 in Pharmaceuticals — cheaper than 99% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.

How much does the SHELTER PHARMA LIMITED share price move in a day?

On a typical session SHELTER PHARMA LIMITED moves 2.21% — that is the median absolute close-to-close move across its last 248 trading days. MarketPing measures each filing's price reaction against it.

Where can I track SHELTER PHARMA LIMITED's announcements?

Every NSE and BSE filing by SHELTER PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.